The role of 21-hydroxylase in the pathogenesis of adrenal masses: Review of the literature and focus on our own experience

Journal of Endocrinological Investigation

Volumn 30, Issue 7, 2007, Pages 615-623

  Barzon, L ^a   Maffei, P ^a   Sonino, N ^a   Pilon, C ^a   Baldazzi, L ^b   Balsamo, A ^b   Del Maschio, O ^c   Masi, G ^a   Trevisan, M ^a   Pacenti, M ^a   Fallo, Francesco ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c Mestre Hospital   (Italy)

Author keywords

21 hydroxylase; Adrenal tumours; Dexamethasone

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; 3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; ANDROGEN RECEPTOR; ANTIHYPERTENSIVE AGENT; AROMATASE; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; DEXAMETHASONE; ESTROGEN RECEPTOR; FLUORODEOXYGLUCOSE F 18; GLUCOCORTICOID; HYDROCORTISONE; HYDROXYPROGESTERONE; INTERMEDIN; MELANOCORTIN 2 RECEPTOR; SEX HORMONE; STEROID 11BETA MONOOXYGENASE; STEROID 21 MONOOXYGENASE;

ADRENAL CORTEX CARCINOMA; ADRENAL CORTEX TUMOR; ADRENAL INCIDENTALOMA; CARCINOGENESIS; CELL PROLIFERATION; COMPUTER ASSISTED TOMOGRAPHY; CONGENITAL ADRENAL HYPERPLASIA; CORTICOTROPIN RELEASE; ENZYME ACTIVITY; GENE CONVERSION; GENE EXPRESSION PROFILING; HORMONE ACTION; HUMAN; HYPERTENSION; LOW DRUG DOSE; MICROARRAY ANALYSIS; MUTATIONAL ANALYSIS; NONFUNCTIONING PITUITARY ADENOMA; NONHUMAN; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PROMOTER REGION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; STEROID 21 MONOOXYGENASE DEFICIENCY;

EID: 35348858173     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03346358     Document Type: Review

References (64)

1. Barzon L, Sonino N, Fallo F, Palù G, Boscaro M. Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol 2003, 149: 273-85.
2. Kloos RT, Gross MD, Francis IR, Korobkin M, Shapiro B. Incidentally discovered adrenal masses. Endocr Rev 1995, 16: 460-84.
3. Merke DP, Bornstein SR. Congenital adrenal hyperplasia. Lancet 2005, 365: 2125-36.
4. White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev 2000, 21: 245-91.
5. Ravichandran R, Lafferty F, McGinniss MJ, Taylor HC. Congenital aclrenal hyperplasia presenting as massive adrenal incidentalomas in the sixth decade of life: report of two patients with 21-hydroxylase deficiency. J Clin Endocrinol Metab 1996, 81: 1776-9.
6. Nagasaka S, Kubota K, Motegi T, et al. A case of silent 21-hydroxylase deficiency with persistent adrenal insufficiency after removal of an adrenal incidentaloma. Clin Endocrinol (Oxf) 1996, 44: 111-6.
7. Barzon L, Scaroni C, Sonino N, et al. Incidentally discovered adrenal tumors: endocrine and scintigraphic correlates. J Clin Endocrinol Metab 1998, 83: 55-62.
8. Paine AH, Hales DB. Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. Endocr Rev 2004, 25: 947-70.
9. Pezzi V, Mathis JM, Rainey WE, Carr BR. Profiling transcript levels for steroidogenic enzymes in fetal tissues. J Steroid Biochem Mol Biol 2003, 87: 181-9.
10. John ME, John MC; Boggaram V, Simpson ER, Waterman MR. Transcriptional regulation of steroid hydroxylase genes by corticotropin. Proc Natl Acad Sci USA 1986, 83: 4715-9.
11. 2+-regulated expression of 21-hydroxylase cytochrome P450 in H295R human adrenocortical cells. J Clin Endocrinol Metab 1998, 83: 1592-7.
12. Endoh A, Yang L, Hornsby PJ. CYP21 pseudogene transcripts are much less abundant than those from the active gene in normal human adrenocortical cells under various conditions in culture. Mol Cell Endocrinol 1998, 137: 13-9.
13. Shannon MF, Pell LM, Lenardo MJ, et al. A novel tumor necrosis factor-responsive transcription factor which recognizes a regulatory element in hemopoetic growth factor genes. Mol Cell Biol 1990, 10: 2950-9.
14. Wijesuriya SD, Zhang G, Dardis A, Miller WL. Transcriptional regulatory elements of the human gene for cytochrome P450c21 (steroid 21-hydroxylase) lie within intron 35 of the linked C4B gene. J Biol Chem 1999, 274: 38097-106.
15. Tee MK, Babalola GO, Aza-Blanc P, Speek M, Gitelman SE, Miller WL. A promoter within intron 35 of the human C4A gene initiates abundant adrenal-specific transcription of a 1 kb RNA: location of a cryptic CYP21 promoter element? Hum Mol Genet 1995, 4: 2109-16.
16. Sirianni R, Seely JB, Attia G, et al. Liver receptor homologue1 is expressed in human steroidogenic tissues and activates transcription of genes encoding steroidogenic enzymes. J Enclocrinol 2002, 174: R13-7.
17. Bavner A, Sanyal S, Gustafsson JA, Treuter E. Transcriptional corepression by SHP: molecular mechanisms and physiological consequences. Trends Endocrinol Metab 2005, 165 478-88.
18. Lee HJ, Lee YF, Chang C. TR4 orphan receptor represses the human steroid 21-hydroxylase gene expression through the monomeric AGGTCA motif. Biochem Biophys Res Comm 2001, 285: 1361-8.
19. Liu J, Li XD, Vaheri A, Voutilainen R. DNA methylation affects cell proliferation, cortisol secretion and steroidogenic gene expression in human adrenocortical NCI-H295R cells. J Mol Endocrinol 2004, 33: 651-62.
20. Coulter CL, Jaffe RB. Functional maturation of the primate fetal adrenal in vivo: 3. Specific zonal localization and developmental regulation of CYP21A2 (P450c21) and CYP11B1/CYP11 B2 (P450c11/aldosterone synthase) lead to integrated concept of zonal and temporal steroid biosynthesis. Endocrinology 1998, 139: 5144-50.
21. Narasaka T, Suzuki T, Moriya T, Sasano H. Temporal and spatial distribution of corticosteroidogenic enzymes immunoreactivity in developing human adrenal. Mol Cell Endocrinol 2001, 174: 111-20.
22. Sasano H, Suzuki T, Nagura H, Nishikawa T. Steroidogenesis in human adrenocortical carcinoma: biochemical activities, immunohistochemistry, and in situ hybridization of steroidogenic enzymes and histopathologic study in nine cases. Hum Pathol 1993, 24: 397-404.
23. Ogo A, Haji M, Yanase T, Kato K, Nawata H. The modification and expression of 21-hydroxylase gene in normal human adrenal gland and adrenal cancer. J Endocrinol Invest 1991, 14: 831-7.
24. Rácz K, Pinet F, Marton T, Szende B, Gláz E, Corvol P. Expression of steroidogenic enzyme messenger ribonucleic acids and corticosteroid production in aldosterone-producing and "nonfunctioning" adrenal adenomas. J Clin Endocrinol Metab 1993, 77: 677-82.
25. Beuschlein F, Schulze E, Mora P, et al. Steroid 21-hydroxylase mutations and 21-hydroxylase messenger ribonucteic acid expression in human adrenocortical tumors. J Clin Endocrinol Metab 1998, 83: 2585-8.
26. Bassett MH, Mayhew B, Rehman K, et al. Expression profiles for steroidogenic enzymes in adrenocortical disease. J Clin Endocrinol Metab 2005, 90: 5446-55.
27. Assié G, Auzan C, Gasc JM, et al. Steroidogenesis in aldosterone-producing adenoma revisited by transcriptome analysis. J Clin Endocrinol Metab 2005, 90: 6638-49.
28. Balsamo A, Cacciari E, Baldazzi L, et al. CYP21 analysis and phenotype/ genotype relationship in the screened population of the Italian Emilia-Romagna region. Clin Endocrinol (Oxf) 2000, 53: 117-25.
29. Jaresch S, Komely E, Kley HK, Schlaghecke R. Adrenal incidentaloma and patients with homozygous or heterozygous congenital adrenal hyperplasia. J Clin Endocrinol Metab 1992, 74: 685-9.
30. Wang J, Bissada MA, Williamson HO, Yakout H, Bissada NK. Adrenal tumors associated with inadequately treated congenital adrenal hyperplasia. Can J Urol 2002, 9: 1563-4.
31. Kurtoglu S, Atabek ME, Keskin M, Patiroglu TE. Adrenocortical adenoma associated with inadequately treated congenital adrenal hyperplasia. J Pediatr Endocrinol Metab 2003, 16: 1311-4.
32. Ravichandran R, Lafferty F, McGinniss MJ, Taylor HC. Congenital adrenal hyperplasia presenting as massive adrenal incidentalomas in the sixth decade of life: report of two patients with 21-hydroxylase deficiency. J Clin Endocrinol Metab 1996, 81: 1776-9.
33. Umpierrez MB, Fackler S, Umpierrez GE, Rubin J. Adrenal myelolipoma associated with endocrine dysfunction: review of the literature. Am J Med Sci 1997, 314: 338-41.
34. Pignatelli D, Vendeira P, Cabral AC. Adrenal incidentalomas: adrenal hemangioma in a patient with congenital adrenal hyperplasia. South Med J 1998, 91: 775-9.
35. Mokshagundam S, Surks MI. Congenital adrenal hyperplasia diagnosed in a man during workup for bilateral adrenal masses. Arch Intern Med 1993, 153: 1389-91.
36. Norris AM, O'Driscoll JB, Mamtora H. Macronodular congenital adrenal hyperplasia in an adult with female pseudohermaphroditism. Eur Radiol 1996, 6: 470-2.
37. Falhammar H, Thoren M. An 88-year-old woman with adrenal tumor and congenital adrenal hyperplasia: connection or coincidence? J Endocrinol Invest 2005, 28: 449-53.
38. Dubey GK, Dotiwalla HH, Choubey BS, Kher A. A case report of virilising adrenal cortical carcinoma. J Assoc Physicians India 1981, 29: 491-3.
39. Bauman A, Bauman CG. Virilizing adrenocortical carcinoma. Development in a patient with salt-losing congenital adrenal hyperplasia. JAMA 1982, 248: 3140-1.
40. Lightner ES, Levine LS. The adrenal incidentaloma. A pediatric perspective. Am J Dis Child 1993, 147: 1274-6.
41. Seppel T, Schlaghecke R. Augmented 17 alpha-hydroxyprogesterone response to ACTH stimulation as evidence of decreased 21-hydroxylase activity in patients with incidentally discovered adrenal tumours ('incidentalomas'). Clin Endocrinol (Oxf) 1994, 41: 445-51.
42. Ambrosi B, Peverelli S, Passini E, et al. Abnormalities of endocrine function in patients with clinically "silent" adrenal masses. Eur J Endocrinol 1995, 132: 422-8.
43. Terzolo M, Osella G, Ali A, et al. Different patterns of steroid secretion in patients with adrenal incidentaloma. J Clin Endocrinol Met 1996, 81: 740-4.
44. Bemini GP, Brogi G, Vivaldi MS, et al. 17-Hydroxyprogesterone response to ACTH in bilateral and monolateral adrenal incidentalomas. J Endocrinol Invest 1996, 19: 745-52.
45. Kjellman M, Holst M, Backdahl M, Larsson C, Farnebo LO, Wedell A. No overrepresentation of congenital adrenal hyperplasia in patients with adrenocortical tumours. Clin Endocrinol (Oxf) 1999, 50: 343-6.
46. Patócs A, Tóth M, Barra C, et al. Hormonal evaluation and mutation screening for steroid 21-hydroxylase deficiency in patients with unilateral and bilateral adrenal incidentalomas. Eur J Endocrinol 2002, 147: 349-55.
47. Baumgartner-Parzer SM, Pauschenwein S, Waldhäusl W, Pölzler K, Nowotny P, Vierhapper H. Increased prevalence of heterozygous 21-OH germline mutations in patients with adrenal incidentalomas. Clin Endocrinol (Oxf) 2002, 56: 811-6.
48. Barzon L, Boscaro M. Diagnosis and management of adrenal incidentalomas. J Urol 2000, 163: 398-407.
49. Reincke M, Peter M, Sippell WG, Allolio B. Impairment of 11β-hydroxylase but not 21-hydroxylase in adrenal 'incidentalomas'. Eur J Endocrinol 1997, 136: 196-200.
50. Dall'Asta C, Barbetta L, Libe R, Passini E, Ambrosi B. Coexistence of 21-hydroxylase and 11 beta-hydroxylase deficiency in adrenal incidentalomas and in subclinical Cushing's syndrome. Horm Res 2002, 57: 192-6.
51. Toth M, Racz K, Adleff V, et al. Comparative analysis of plasma 17-hydroxyprogesterone and cortisol responses to ACTH in patients with various adrenal tumors before and after unilateral adrenalectomy. J Endocrinol Invest 2000, 23: 287-94.
52. Sadoul JL, Kézachian B, Altare S, Hadjali Y, Canivet B. Apparent activities of 21-hydroxylase, 17alpha-hydroxylase and 17,20-lyase are impaired in adrenal incidentalomas. Eur J Endocrinol 1999, 141: 238-45.
53. Reincke M, Mora P, Beuschlein F, Arlt W, Chrousos GP, Allolio B. Deletion of the adrenocorticotropin receptor gene in human adrenocortical tumors: implications for tumorigenesis. J Clin Endocrinol Metab 1997, 82: 3054-8.
54. Simonian MH, Gill GN. Regulation of the fetal human adrenal cortex: effects of adrenocorticotropin on growth and function of monolayer cultures of fetal and definitive zone cells. Endocrinology 1981, 108: 1769-79.
55. Kimura E, Sonobe MH, Armelin MC, Armelin HA. Induction of FOS and JUN proteins by adrenocorticotropin and phorbol ester but not by 3′,5′-cyclic adenosine monophosphate derivatives. Mol Endocrinol 1993, 7: 1463-71.
56. Zwermann O, Schulte DM, Reincke M, Beuschlein F. ACTH 1-24 inhibits proliferation of adrenocortical tumors in vivo. Eur J Endocrinol 2005, 153: 435-44.
57. Clark AJ, Weber A. Adrenocorticotropin insensitivity syndromes. Endocr Rev 1998, 19: 828-43.
58. Lowry PJ, Silas L, McLean C, Linton EA, Estivariz FE. Pro-gammamelanocyte-stimulating hormone deavage in adrenal gland undergoing compensatory growth. Nature 1983, 306: 70-3.
59. Willenberg HS, Haase M, Papewalis C, Schott M, Scherbaum WA, Bornstein SR. Corticotropin-releasing hormone receptor expression on normal and tumorous human adrenocortical cells. Neuroendocrinology 2005, 82: 274-81.
60. Bornstein SR, Ehrhart M, Scherbaum WA, Pfeiffer EF. Adrenocortical atrophy of hypophysectomized rats can be reduced by corticotropin-releasing hormone (CRH). Cell Tissue Res 1990, 260: 161-6.
61. Knochenhauer ES, Cortet-Rudelli C, Cunnigham RD, Conway-Myers BA, Dewailly D, Azziz R. Carriers of 21-hydroxylase deficiency are not at increased risk for hyperandrogenism. J Clin Endocrinol Metab 1997, 82: 479-85.
62. Montanaro D, Maggiolini M, Recchia AG, et al. Antiestrogens upregulate estrogen receptor β expression and inhibit human adrenocortical cell proliferation. J Mol Endocrinol 2005, 35: 245-56.
63. Lefebvre H, Duparc C, Chartrel N, et al. Intraadrenal adrenocorticotropin production in a case of bilateral macronodular adrenal hyperplasia causing Cushing's syndrome. J Clin Endocrinol Metab 2003, 88: 3035-42.
64. Barzon L, Scaroni C, Sonino N, Fatio F, Paoletta A, Boscaro M. Risk factors and long-term follow-up of adrenal incidentalomas. J Clin Endocrinol Metab 1999, 84: 520-6.